UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 216

Sortiert nach

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

The oncologist (Dayton, Ohio), 2021-11, Vol.26 (11), p.e2061-e2069

2021

Link zum Volltext

Verfügbarkeit prüfen

Successful treatment of local anaesthetic toxicity using intralipid 20% emulsion following intrathoracic bupivacaine overdose in a cat

JFMS open reports, 2022-01, Vol.8 (1), p.205511692211045

2022

Link zum Volltext

Verfügbarkeit prüfen

Concordance of the Histopathologic Diagnosis of Concurrent Duodenal and Ileal Biopsy Specimens in Dogs

Animals (Basel), 2021-10, Vol.11 (10), p.2938

2021

Link zum Volltext

Verfügbarkeit prüfen

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy

Frontiers in endocrinology (Lausanne), 2022-03, Vol.13, p.779915-779915

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920982859-1758835920982859

2020

Link zum Volltext

Verfügbarkeit prüfen

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

Frontiers in oncology, 2021-07, Vol.11, p.707050-707050

2021

Link zum Volltext

Verfügbarkeit prüfen

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Journal for immunotherapy of cancer, 2021-07, Vol.9 (7), p.e002851

2021

Link zum Volltext

Verfügbarkeit prüfen

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade

Frontiers in oncology, 2021-06, Vol.11, p.701345-701345

2021

Link zum Volltext

Verfügbarkeit prüfen

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors

Cancer medicine (Malden, MA), 2020-04, Vol.9 (8), p.2752-2760

2020

Link zum Volltext

Verfügbarkeit prüfen

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation

Journal of the advanced practitioner in oncology, 2019-03, Vol.10 (2), p.167-174

2019

Link zum Volltext

Verfügbarkeit prüfen

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience

Journal of Immunotherapy and Precision Oncology, 2022-08, Vol.5 (3), p.52-57

2022

Link zum Volltext

Verfügbarkeit prüfen

223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A242-A242

2020

Link zum Volltext

Verfügbarkeit prüfen

44 Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A45-A46

2020

Link zum Volltext

Verfügbarkeit prüfen

Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib

Cancer treatment and research communications, 2021, Vol.28, p.100393-100393, Article 100393

2021

Link zum Volltext

Verfügbarkeit prüfen

45 Body composition as a predictive and prognostic biomarker in advanced urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICI)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A47-A48

2020

Link zum Volltext

Verfügbarkeit prüfen

Nausea and Vomiting: Managing Side Effects From PARP Inhibitors.(INSIGHTS FROM AN ONCOLOGY PHARMACIST)(poly (adenosine diphosphate-ribose) polymerase)

Oncology (Williston Park, N.Y.), 2019-02, Vol.33 (2), p.58

2019

Link zum Volltext

Verfügbarkeit prüfen

Nomograms are key decision-making tools in prostate cancer radiation therapy

Urologic oncology, 2018-06, Vol.36 (6), p.283-292

2018

Link zum Volltext

Verfügbarkeit prüfen

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Journal of the advanced practitioner in oncology, 2019-07, Vol.10 (5), p.501-507

2019

Link zum Volltext

Verfügbarkeit prüfen

Nausea and Vomiting: Managing Side Effects From PARP Inhibitors

Oncology (Williston Park, N.Y.), 2019-02, Vol.33 (2), p.58-61

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes and Racial Disparities in Metastatic Hormone‐Sensitive Prostate Cancer in the Era of Novel Treatment Options

The oncologist (Dayton, Ohio), 2021-11, Vol.26 (11), p.956-964

2021

Link zum Volltext

Verfügbarkeit prüfen

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

The oncologist (Dayton, Ohio), 2020-03, Vol.25 (3), p.e484-e491

2020

Link zum Volltext

Verfügbarkeit prüfen

Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors

The oncologist (Dayton, Ohio), 2021-05, Vol.26 (5), p.397-405

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune‐Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

The oncologist (Dayton, Ohio), 2021-10, Vol.26 (10), p.e1742-e1750

2021

Link zum Volltext

Verfügbarkeit prüfen

The impact of body mass index (BMI) on the safety and outcomes of small molecule inhibitors (SMI) in gastrointestinal cancer

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.144-144

2020

Link zum Volltext

Verfügbarkeit prüfen

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

The oncologist (Dayton, Ohio), 2023-03, Vol.28 (3), p.239-245

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 216

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(190)

Publikationsform

Artikel
(158)
Buchkapitel
(43)
Bücher
(6)
Reviews
(5)
Berichte
(4)

Sprache

Englisch
(215)
Japanisch
(15)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

Successful treatment of local anaesthetic toxicity using intralipid 20% emulsion following intrathoracic bupivacaine overdose in a cat

Concordance of the Histopathologic Diagnosis of Concurrent Duodenal and Ileal Biopsy Specimens in Dogs

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy

Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience

223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy

44 Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib

45 Body composition as a predictive and prognostic biomarker in advanced urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICI)

Nausea and Vomiting: Managing Side Effects From PARP Inhibitors.(INSIGHTS FROM AN ONCOLOGY PHARMACIST)(poly (adenosine diphosphate-ribose) polymerase)

Nomograms are key decision-making tools in prostate cancer radiation therapy

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Nausea and Vomiting: Managing Side Effects From PARP Inhibitors

Clinical Outcomes and Racial Disparities in Metastatic Hormone‐Sensitive Prostate Cancer in the Era of Novel Treatment Options

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors

Immune‐Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

The impact of body mass index (BMI) on the safety and outcomes of small molecule inhibitors (SMI) in gastrointestinal cancer

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Suchergebnisse filtern